84539-07-1

Basic information

• Product Name: 3,5-DIBROMO-N,N-DIMETHYLPYRAZINAMINE
• Synonyms: 3,5-DIBROMO-N,N-DIMETHYLPYRAZINAMINE;2-Pyrazinamine,3,5-dibromo-N,N-dimethyl-;(3,5-Dibromo-pyrazin-2-yl)-dimethyl-amine
• CAS NO: 84539-07-1
• Molecular Formula: C₆H₇Br₂N₃
• Molecular Weight: 280.96
• Mol File: 84539-07-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 299.952°C at 760 mmHg
• Flash Point: 135.206°C
• Appearance: /
• Density: 1.921g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.631
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3,5-DIBROMO-N,N-DIMETHYLPYRAZINAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIBROMO-N,N-DIMETHYLPYRAZINAMINE(84539-07-1)
• EPA Substance Registry System: 3,5-DIBROMO-N,N-DIMETHYLPYRAZINAMINE(84539-07-1)

Safety Data

• Hazardous Substances Data: 84539-07-1(Hazardous Substances Data)

Usage

General Description

3,5-DIBROMO-N,N-DIMETHYLPYRAZINAMINE is a chemical compound with the molecular formula C6H10Br2N4. It is a white to light yellow solid that is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 3,5-DIBROMO-N,N-DIMETHYLPYRAZINAMINE is also known for its use as a reactant in the creation of novel heterocyclic compounds and organic functional groups. 3,5-DIBROMO-N,N-DIMETHYLPYRAZINAMINE is soluble in organic solvents such as ethanol, ethyl acetate, and chloroform, and is stable under normal conditions when stored properly. However, it is important to handle and store this compound with proper safety measures due to its potentially harmful nature.

InChI:InChI=1/C6H7Br2N3/c1-11(2)6-5(8)10-4(7)3-9-6/h3H,1-2H3

Upstream product

• 13134-49-1 3-(dimethylamino)pyrazine 1-oxide 
• 5214-29-9 2-Dimethylamino-pyrazin 
• 24241-18-7 2-amino-3,5-dibromopyrazine 
• 74-88-4 methyl iodide 
• 894808-28-7 3,5-dibromo-N-methylpyrazin-2-amine 

Downstream Products

• 894808-41-4 5-Bromo-N,N-dimethyl-3-(4-methyl-1,4-diazepan-1-yl)pyrazin-2-amine 

Relevant articles and documents

2,3-Diaminopyrazines as rho kinase inhibitors

Inhibition of rho kinase (ROCK) has been recognized as an important target for a number of diseases, including glaucoma. Herein we report SAR development around two hits from a kinase library that led to the discovery of the ROCK inhibitor compound 38. In vitro and in vivo analysis of this compound, including its effects in a monkey model of glaucoma will be discussed.

Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions

Methods for using aminopyrazine analogs to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of aminopyrazine analogs, are also disclosed.

Bromination of Some Pyridine and Diazine N-Oxides

Selected monosubstituted pyridines, pyrazines, pyrimidines, and their N-oxides, having an electron-donating substituent, were successfully brominated under very mild conditions.The N-oxide function itself is not sufficient to cause these ?-deficient systems to undergo electrophilic aromatic halogenation.Only strongly electron-donating substituents (amino groups) activate the heterocyclic nucleus toward bromination.These substituents direct the electrophilic substitution ortho/para to them with or without the N-oxide group present.Pyridine and diazines with moderately activating substituents such as alkoxy groups are brominated only when their ortho/para activation is augmented by the activation of the N-oxide funtion.Failure to brominate 5-methoxypyrimidine 1-oxide may well reflect the greater ? deficiency of the pyrimidine ring.